|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
3/13/2012 9:30:43 AM
DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) (“Alkermes”) today announced the completion of an underwritten public offering of 24,150,000 ordinary shares held by a subsidiary of Elan Corporation, plc (“Elan”) at a price to the public of $16.50 per share, which includes 3,150,000 ordinary shares in connection with the full exercise by the underwriters of their option to purchase additional shares. Alkermes did not receive any proceeds from the offering, and its total number of ordinary shares outstanding did not change as a result of the offering. Citigroup, Jefferies & Company, Inc. and Morgan Stanley acted as joint book-running managers. Berenberg Bank and Cowen and Company, LLC acted as co-managers for the offering. The Elan subsidiary continues to own 7,750,000 ordinary shares, which are subject to transfer restrictions set forth in a shareholder’s agreement by and between Alkermes, Elan and the Elan subsidiary.
|
|
|
|
|
|
|
|
|
|
|